Atrial Fibrillation Service

Slides:



Advertisements
Similar presentations
Antithrombotic Therapy for Stroke Prevention in Atrial Fibrillation.
Advertisements

Atrial Fibrillation Cardiovascular ISCEE 26th October 2010.
Poole AF/ A Flutter Clinic 2011 Diane Bruce Consultant Cardiologist PHNHSFT.
New Atrial Fibrillation/Flutter Pathway and GRASP Tool
Educational Event 23rd & 24th January 2013
Managing anticoagulation in atrial fibrillation Dr Katy Rice June 2011.
NOAC but NICE Conference 16th July 2013.
1 GRASP-AF Audit - Intro 8 th July 2010 Mark Gregory.
Educational Event 23rd & 24th January 2013
New Atrial Fibrillation/Flutter Pathway and GRASP Tool
Emergency/Urgent Referral* (3) -Pt acutely unwell with palpitations -Pt with haemodyanically unstable acute onset AF -2 nd /3 rd heart block -Exercise.
ATRIAL FIBRILLATION.
AF and the New Oral Anti-Coagulants
Screening and diagnosis of AF and stratifying stroke risk.
Stratifying stroke risk to guide antithrombotic therapy in patients with AF.
9th October 2013 Dr Julian Tomkinson
Atrial fibrillation Cardiology #2 Gimadeeva A.D..
New Oral Anticoagulants (NOACs) Dabigatran and Rivaroxaban for the prevention of stroke and systemic embolism in nonvalvular atrial fibrillation Dr Dipti.
CLINICAL CASES.
DR DIPTI CHITNAVIS HAEMATOLOGY CONSULTANT WEST SUFFOLK HOSPITAL JANUARY 2014 Update on the new oral anticoagulants; 12 months on.
ARISTOTLE TRIAL Dr R Nyabadza GPST1 Ward 32. Structure AF, stroke and CHA 2 -DS 2 VASC Anticoagulant choices ARISTOTLE trial Cost NICE guidance and the.
Study by: Granger et al. NEJM, September 2011,Vol No. 11 Presented by: Amelia Crawford PA-S2 Apixaban versus Warfarin in Patients with Atrial Fibrillation.
Atrial Fibrillation Stroke Prevention with Oral Anticoagulants Why is there discordance between guideline committees & specialists when the data is based.
AF and NOACs An UPDATE JULY 2014
Arrhythmias: The Good, the Bad and the Ugly
Atrial Fibrillation Steve McGlynn
Atrial Fibrillation. Statistics 1.5% of people over 65 have AF 1.5% of people over 65 have AF 5x increased risk of stroke 5x increased risk of stroke.
APIXABAN NELLA SPAF 21 maggio 2015 ROMA Dott. Sergio Agosti Cardiologo, Ospedale Novi Ligure (AL)
DR ABUL AZIM CONSULTANT IN ELDERLY MEDICINE & STROKE STROKE AND ATRIAL FIBRILLATION AND THE ROLE OF THE NOAC.
Atrial Fibrillation Warfarin and its newer alternatives
  Warfarin Dabigatran Rivaroxaban Apixaban Edoxaban Target
Dr Avinash Haridas Pillai
The imminent NICE guidelines for AF – what are the implications? David Hargroves, Consultant Physician, Clinical Lead for Stroke Medicine, East Kent Hospitals.
European Heart Journal 2010 European Heart Rhythm Association (EHRA); Endorsed by the European Association for Cardio-Thoracic.
Atrial Fibrillation Dr Nidhi Bhargava 8/10/13.
Atrial Fibrillation Andreas Stein Robert Smith, M.D. August 11, 2003.
Atrial Fibrillation Current Management Strategies.
Atrial Fibrillation Now and Then Min-Yen Han,M.D. November 15,2014.
Atrial Fibrillation and Anticoagulation
Accuracy of CHADS2, CHA2DS2- VASC and HAS-BLED scores in evaluation of stroke and bleeding risk First author: Alexandra Murar Co-author: Andreia Gherasâm.
Treatment of Atrial Fibrillation M Samson – PGY-2 Riverside Campus July 17, 2015 Academic Day.
Exercise Management Atrial Fibrillation Chapter 9.
Presented by Renato D. Lopes, MD, PhD, Duke Clinical Research Institute, Duke University, USA for the ARISTOTLE investigators. Efficacy and Safety of Apixaban.
Preoperative Hemoglobin A1c and the Occurrence of Atrial Fibrillation Following On-pump Coronary Artery Bypass surgery in Type-2 Diabetic Patients Akbar.
Case study - patient presenting with newly diagnosed NVAF with prior CAD Full Prescribing Information is provided at the end of this presentation EUAPI581k;
The Case for Rate Control: In the Management of Atrial Fibrillation Charles W. Clogston, M.D. Cardiologist CHI St. Vincent Heart Clinic Arkansas April.
Palpitations & Atrial Fibrillation Dr Mehul B Dhinoja, Consultant Cardiologist & Electrophysiologist BMI The London Independent Hospital.
Optimising Anticoagulation in the New Oral Anticoagulant Clinic for People with AF Satinder Bhandal Consultant Anticoagulation Pharmacist February 2015.
Antithrombotic Therapy in Atrial Fibrillation Copyright: American College of Chest Physicians 2012 © Antithrombotic Therapy and Prevention of Thrombosis,
Bleeding After Initiation of Multiple Antithrombotic Drugs, Including Triple Therapy, in Atrial Fibrillation Patients Following Myocardial Infarction and.
Stoke On Trent CCG – Atrial Fibrillation Service AF Nurse in GP Practice Interfacing Primary and Secondary Care for AF Stroke Prevention Jodie Williams.
Clinical pathway for people with atrial fibrillation or at risk of atrial fibrillation Dr Ruth Chambers OBE LTC Priority Lead, West Midlands Academic Health.
Prevention of thromboembolism in AF ACC/AHA/ESC Guidelines Jin-Bae Kim, MD, PhD Arrhythmia Service, Division of Cardiology Cardiovascular Center, Kyung.
R4 문정락 / IC prof. 김진배 Lancet Haematol 2015;2: e150–59.
Net clinical benefit of OAC
Case 66 year old male with PMH of HTN, DM, ESRD on renal replacement TIW, stroke in 2011 with right side residual weakness, atrial fibrillation, currently.
Direct Comparison of Dabigatran, Rivaroxaban, and Apixaban for Effectiveness and Safety in Non-valvular Atrial Fibrillation.
You can never be too Thin…. An Update on NOACs
Volume 28, Issue 6, Pages (December 2012)
Anticoagulation in Atrial Fibrillation
Management of atrial fibrillation. Patterns of Atrial Fibrillation.
No evidence that AF type significantly impacts stroke risk
Use of NOACs is contraindicated for AF patients with mechanical prosthetic valves or moderate- severe mitral stenosis (usually of rheumatic origin). Although.
Atrial fibrillation (AF) and flutter
Barriers to Oral Anticoagulant Use for Stroke Prevention in AF
ATHENA Trial Presented at Heart Rhythm 2008 in San Francisco, USA
Fibrillazione atriale
Oral Anticoagulants in AFa,b A Brief History.
Selecting NOACs for High-Risk Patients
NICE 2014 Check pulse in patients presenting with:
Presentation transcript:

Atrial Fibrillation Service Jayne Woolley Arrhythmia Specialist Nurse Royal Glamorgan Hospital This template can be used as a starter file to give updates for project milestones. Sections Sections can help to organize your slides or facilitate collaboration between multiple authors. On the Home tab, under Slides, click Section, and then click Add Section. Notes Use the Notes pane for delivery notes or to provide additional details for the audience. You can see these notes in Presenter View during your presentation. Keep in mind the font size (important for accessibility, visibility, videotaping, and online production) Coordinated colors Pay particular attention to the graphs, charts, and text boxes. Consider that attendees will print in black and white or grayscale. Run a test print to make sure your colors work when printed in pure black and white and grayscale. Graphics, tables, and graphs Keep it simple: If possible, use consistent, non-distracting styles and colors. Label all graphs and tables.

Atrial Fibrillation Service In-patient referrals for New onset/Incidental finding AF Advice and support to medical team Provision of patient information and counselling Weekly AF MDT meeting Follow-up clinics Dronedarone – monthly monitoring Anticoagulation/NOAC counselling initiation

Atrial fibrillation Service Both Rate/Rhythm control need : Stroke risk assessment CHADS2 – 0/1 reassess risk CHA2DS2VASc score 1 anticoagulation to be considered 2 anticoagulation recommended

Atrial Fibrillation Service HASBLED score Hypertennsion (systolic > 160mmHG) 1 point Abnormal renal/liver function (chronic dialysis/transplantation, serum creatinine >200mmol/L chronic hepatic disease, bilirubin 2 x upper limit alkaline phosphatase 3 x upper limit 1 point each Stroke 1 point Bleeding 1 point previous bleeding history, anaemia etc Liable INR’s 1 point < 60% in theraputic range, unstable high INRs Elderly > 65yrs of age 1 point Drugs/Alcohol concomitant use of drugs , antiplatelet agents, alcohol abuse 1 point each SCORE OF >3 HIGH RISK

Atrial Fibrillation Service NOAC s for stroke prevention in adults with non-valvular AF with 1 or more risk factors: Stroke/TIA/Systemic embolism Symptomatic heart failure (NYHA) class >2 Left ventricular failure, ejection fraction <40% Age >75 yrs Age >65 plus one of the following: Diabetes mellitus, coronary artery disease or hypertension Dabigatran, Apixaban and Rivaroxaban Pros: Cons: Lower intercranial haemorrhage No known reversible agent Rapid onset/short half life No monitoring No monitoring Heartburn/bloating/diarrhoea No food restrictions 100% compliance No alcohol restrictions Less drug interactions

Atrial Fibrillation Service Elective cardioversion Receive referrals Arrange anticoagulation and required investigations Recording weekly INR results (warfarin) Pre-assessment clinics If on NOAC declaration is signed by patient Cardioversion procedure 1 + 6 month follow-up clinics

Atrial Fibrillation Service Elective cardioversion every 4 weeks 5-6 patients per list 13 currently waiting at least 2 extra lists per year

Waiting Times for Cardioversion Min 4 Weeks Max 12 Weeks Longer if subtheraputic INR

Atrial Fibrillation Service Cardioversion April 2013-April 2014 88 patients listed 2 extras lists 82 successful - 93% 6 unsuccessful on the day - 7% (rounded up) max 3 shocks delivered, AF in theatre

Cancellations and Deferred Patients April 2013 – April 2014 5 – SR on workup/Pre-assessment Deferred 2 – raised TSH (above 10) 12 – low INR * If any of these issues caused a schedule delay or need to be discussed further, include details in next slide.

Atrial Fibrillation Service Pre/Post cardioversion Weekly INRs 3 weeks before Preferred range 2.5 to 3.0 (reduced risk of stroke at higher level) if INR below 2 in the 3 weeks then they are cancelled Weekly INRs 4 weeks post cardioversion level) ESC and NICE state that anticoagulation should continue and not be interrupted for minimum of 4 weeks post cardioversion Thromboembolic complications of direct cardioversion are generally related to inadequate intensity of anticoagulation. The INR at the time of conversion is very important. Anticoagulation is necessary for the conversion of atrial flutter as it is for atrial fibrillation. The INR should be 2.5 or more at the time of cardioversion of any atrial arrhythmia that has lasted for more than 2 days. J Am Coll Cardiol 2002

Thank You!